TABLE 1.
Classification of historical triptan response (mITT population)
| Pooled ACHIEVE participants, n (%) | ||
|---|---|---|
| Placebo | Ubrogepant 50 mg | |
| (n = 912) | (n = 887) | |
| Triptan responder | 350 (38.4) | 332 (37.4) |
| Triptan‐insufficient responder a | 223 (24.5) | 228 (25.7) |
| Insufficient efficacy | 174 (78.0) | 185 (81.1) |
| Insufficient tolerability | 38 (17.0) | 37 (16.2) |
| Contraindications | 7 (3.1) | 5 (2.2) |
| Triptan naive | 339 (37.2) | 327 (36.9) |
Abbreviation: mITT, modified intent‐to‐treat.
a
Data missing for n = 2 placebo (ACHIEVE I) and n = 2 placebo and n = 1 ubrogepant 50 mg (ACHIEVE II).